A Man Developed a Rare Brain Condition Linked to Vitamin Deficiency While Taking Semaglutide | Research

The takeaway

A 37-year-old non-alcoholic man developed Wernicke encephalopathy (a serious brain condition caused by thiamine deficiency) while using semaglutide, highlighting a rare but important safety concern with GLP-1 drugs.

Non-alcoholic Wernicke encephalopathy
Developed in a 37-year-old male in the setting of semaglutide use — a rare but serious nutritional complication

What the researchers found

Non-alcoholic Wernicke encephalopathy occurred in a 37-year-old male patient in the setting of semaglutide use, presenting with dysphagia, slurred speech, word-finding difficulty, and restricted extraocular movements.

Why it matters

As millions of people use semaglutide for weight loss and diabetes, clinicians need to be aware that severe appetite suppression can lead to dangerous nutritional deficiencies. Wernicke encephalopathy can cause permanent brain damage if not recognized and treated promptly with thiamine.

The numbers in context

37-year-old male, non-alcoholic. Presented with dysphagia, slurred speech, and word-finding difficulties.

How the study worked

Single case report documenting clinical presentation, diagnostic workup, and association with semaglutide use in a patient with non-alcoholic Wernicke encephalopathy.

Who was studied

37-year-old non-alcoholic male on semaglutide

What this study cannot tell us

Single case report — cannot establish causation between semaglutide and Wernicke encephalopathy. Other contributing factors to malnutrition may not have been fully explored. The overall incidence of this complication with GLP-1 drugs is unknown.

How to read the evidence

Preliminary evidence from a single case report. Establishes a plausible association but cannot prove causation. Useful for clinical awareness.

When this study was published

Published in 2024. Relevant to the rapidly expanding use of GLP-1 drugs for weight management.

The bigger picture

GLP-1 drugs like semaglutide dramatically reduce appetite, which is their intended effect for weight loss. However, this case illustrates a serious unintended consequence: when appetite suppression leads to severely inadequate nutrition, it can cause life-threatening vitamin deficiencies. As GLP-1 drug use expands rapidly, monitoring nutritional status becomes an important safety consideration.

Questions still open

How common is clinically significant thiamine deficiency among patients on GLP-1 receptor agonists?
Should routine thiamine monitoring or supplementation be recommended for patients on appetite-suppressing medications?
Are certain patient populations at higher risk for nutritional deficiencies while taking semaglutide?

Common questions

What is Wernicke encephalopathy and how is it treated?

Wernicke encephalopathy is a neurological emergency caused by severe thiamine (vitamin B1) deficiency. It causes confusion, eye movement problems, and coordination difficulties. It's treated with urgent IV thiamine supplementation, and early treatment is critical to prevent permanent brain damage.

Should people taking semaglutide worry about this?

This is a rare complication, but it underscores the importance of maintaining adequate nutrition while taking appetite-suppressing medications. Patients should ensure they eat balanced meals even with reduced appetite, and consider a multivitamin. Report any neurological symptoms to a doctor immediately.

Read the original research

Wernicke Encephalopathy Associated With Semaglutide Use.

Cureus, 16(6), e61783

View on PubMed ↗Publisher’s paper ↗

Citation

Sheth, Krishna; Garza, Elizabeth; Saju, Ajith; Nazir, Natasha; Agarwal, Aditya. (2024). Wernicke Encephalopathy Associated With Semaglutide Use.. Cureus, 16(6), e61783. https://doi.org/10.7759/cureus.61783